SCHEDULE: Vanguard Group Amends Amphastar Stake, Reports 0% Ownership

The Vanguard Group has filed an amended Schedule 13G for Amphastar Pharmaceuticals Inc., reporting zero beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed Amendment No. 5 to its Schedule 13G for Amphastar Pharmaceuticals Inc. (CUSIP: 03209R103).
• The filing reports that The Vanguard Group beneficially owns 0 shares of Amphastar Pharmaceuticals Inc. Common Stock, representing 0% of the class.
• This change in reported ownership is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these newly disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update regarding The Vanguard Group's internal reporting structure, with no direct positive or negative implications for Amphastar Pharmaceuticals Inc.'s operational or financial outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Amphastar Pharmaceuticals Inc.'s operations or financial performance.

Management Comments

• The Vanguard Group, Inc. underwent an internal realignment on January 12, 2026.
• Certain subsidiaries or business divisions will now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in accordance with SEC Release No. 34-39538.
• These subsidiaries and/or business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that internal realignments and subsequent changes in reporting structures, such as disaggregated beneficial ownership filings, are administrative actions common among large, diversified asset management firms like The Vanguard Group. These changes typically reflect internal operational adjustments rather than a shift in investment strategy concerning the underlying issuer.

Stakeholder Impact

• Shareholders of Amphastar Pharmaceuticals Inc. may note a change in the reported beneficial ownership by The Vanguard Group, though the underlying investment by Vanguard's broader entities may persist through disaggregated reporting by its subsidiaries.

Key Dates

Keywords

Amphastar Pharmaceuticals, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, SEC filing, common stock